Jan Müller-Berghaus is paediatrician by training and joined the Paul-Ehrlich-Institut as clinical expert in 2005. The Paul-Ehrlich-Institut is the German Federal Agency for Vaccines and Biomedicines and is actively participating in all aspects of German and European marketing authorisation as well as clinical trial authorisation. In 2011 he was elected as co-opted member of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), since 2017 he is member of the Committee for Advanced Therapies (CAT) of EMA.

Additional professional experience includes basic research in immunology at the University of Pittsburgh (USA) and translational research in the immunotherapy of cancer (German Cancer Research Center, Heidelberg, Germany).